Abstract | OBJECTIVE: METHODS: SCID-mouse acute myeloid leukemia model was established by injecting HL-60 cells through tail vein. GM-CSF was labeled with 131I by the chloramines-T method. SCID mice were randomly divided into 6 groups. Groups I, II and III treatment groups were given 9.25 x 10(5), 22.20 x 10(5) and 37.00 x 10(5) Bq of 131I-GM-CSF, respectively. Group IV was given 131I. Group V was given blending of 131I and GM-CSF. Group VI was control. Changes of HL-60 cells in blood and marrow, as well as white blood cells, red blood cells and platelets in blood were detected. Survival time of the SCID mice was calculated. RESULT: It was observed that WBC, HL-60 cells in blood and marrow were less in treatment groups than that in control groups, especially in groups II, III. After 2 weeks of treatment, BPC of II, III groups increased remarkably (P < 0.01). Survival time of the SCID mice was prolonged in treatment groups (P < 0.01), especially in group III, the longest survival time of 60 days. CONCLUSION: 131I-GM-CSF could increase leukemic SCID mice survival rate. The therapeutic efficacy of low dose and mediate dose of 131I-GM-CSF is dose-dependent. 131I-GM-CSF is an effective radiation immunity therapy for leukemic mice.
|
Authors | Yang-jia Deng, Shi-feng Lou, Yi-zhi Xu |
Journal | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
(Zhonghua Xue Ye Xue Za Zhi)
Vol. 28
Issue 1
Pg. 33-6
(Jan 2007)
ISSN: 0253-2727 [Print] China |
PMID | 17649724
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Granulocyte-Macrophage Colony-Stimulating Factor
|
Topics |
- Animals
- Antineoplastic Agents
(therapeutic use)
- Dose-Response Relationship, Drug
- Female
- Granulocyte-Macrophage Colony-Stimulating Factor
(therapeutic use)
- HL-60 Cells
- Humans
- Leukemia, Myeloid, Acute
(drug therapy)
- Mice
- Mice, SCID
- Xenograft Model Antitumor Assays
|